The identification of individual biologic molecules is the basis of molecular diagnostics, which is a branch of laboratory medicine. The detection of genetic variations is referred to as molecular diagnostics, and it aims to make detection, diagnosis, subclassification, prognosis, and tracking response to medication easier. Molecular diagnostics is the result of a beneficial collaboration between laboratory medicine, genomics knowledge, and technology in the field of molecular genetics, particularly with recent breakthroughs in molecular genomic technologies. Molecular diagnostics (MDx) has risen to prominence in the clinical diagnostic laboratory, where it has demonstrated benefits in routine detection, fingerprinting, and epidemiologic analysis of pathogenic microbes. The technologies that fuel molecular diagnostics are constantly advancing to help solve some of the obstacles that come with using them, such as increasing their clinical value. The fast-emerging technologies that underpin molecular diagnostics are poised to improve — perhaps even revolutionize — medical diagnosis and treatment. Diagnostic assays are becoming more useful in a wider number of clinical settings as a result of these advancements.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States